首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1529071

罕見疾病治療市場- 按藥物類型（生物製劑、非生物製劑）、治療領域（癌症、呼吸系統疾病、心血管疾病）、患者（成人、兒童）、給藥途徑（口服、注射）-全球預測（ 2024 - 2032））

Rare Disease Treatment Market - By Drug Type (Biologics, Non-biologics), Therapeutic Area (Cancer, Respiratory Disorder, Cardiovascular Disorder), Patient (Adult, Pediatric), Route of Administration (Oral, Injectable) - Global Forecast (2024 - 2032)

出版日期: 2024年05月06日 | 出版商:

Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於醫學研究的進步以及強勁的生物製藥投資，2024 年至 2032 年全球罕見疾病治療市場的複合年成長率將達到 9%。基因療法、精準醫學和標靶治療的突破正在重塑治療方法。此外，生物製藥領域的資金投入和合作的增加正在加速罕見疾病創新療法的開發。這些努力增強了治療選擇並解決了未滿足的醫療需求，創造了一個充滿活力的市場環境，致力於改善全球罕見疾病患者的治療結果和生活品質。

例如，2024 年 4 月，LifeArc 啟動了 4000 萬英鎊的研究中心，旨在為患有罕見疾病的個體發現新的測試、治療和治癒方法。透過促進測試、治療和潛在治癒方法的創新，LifeArc 的計劃有可能加速突破、改善患者的治療效果並擴大全球範圍內有效罕見疾病治療的市場容量。

罕見疾病治療行業根據藥物類型、治療領域、患者、給藥途徑和地區進行分類。

由於其功效和快速起效，注射劑細分市場將在 2024 年至 2032 年間顯著成長。許多罕見疾病需要精確、有針對性的藥物輸送，而注射劑可以提供這種藥物。與口服藥物相比，該方法還確保了更高的生物利用度。通常透過注射給藥的生物製劑和單株抗體的成長進一步推動了這一領域的發展。此外，注射技術的進步和慢性罕見疾病的日益普及也有助於注射劑市場的主導地位。

由於血友病、地中海貧血和鐮狀細胞性貧血等罕見血液疾病的高盛行率，到 2032 年，血液相關疾病領域將取得顯著進展。這些疾病通常需要專門的長期治療和管理，這推動了對創新療法的需求。基因治療、標靶治療的進步和研究經費的增加促進了這一領域的成長。此外，認知的提高和診斷能力的提高確保了血液相關疾病仍然是罕見疾病治療市場的一個重要焦點。

在醫療保健支出增加、患者人數增加和醫療保健基礎設施改善的推動下，亞太地區將在 2024 年至 2032 年間獲得大量市場佔有率。中國、日本和印度等國家正大力投資罕見疾病研究和治療設施。此外，醫療保健專業人員和患者對罕見疾病的認知不斷提高，也推動了該地區的市場成長。亞太地區對醫學研究和創新進步的關鍵貢獻將進一步鞏固其作為罕見疾病治療行業關鍵貢獻者的角色。

產業生態系統分析
產業影響力
- 成長動力
  - 罕見疾病盛行率增加
  - 政府優惠政策
  - 新藥上市數量不斷增加
  - 增加新型治療藥物的研發活動
- 產業陷阱與挑戰
  - 對罕見疾病治療缺乏認知
  - 藥物和治療費用高
成長潛力分析
罕見疾病治療的臨床試驗場景
管道分析
未來市場趨勢
技術景觀
流行病學情景
目前的療法
報銷場景
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

主要趨勢
生物製劑
非生物製品

第 6 章：市場估計與預測：按治療領域，2021 - 2032 年

主要趨勢
癌症
血液相關疾病
中樞神經系統
呼吸系統疾病
肌肉骨骼疾病
心血管疾病
其他治療領域

第 7 章：市場估計與預測：按患者分類，2021 - 2032 年

主要趨勢
成人
兒科

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
可注射

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 瑞士
- 瑞典
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 印尼
- 泰國
- 越南
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 智利
- 哥倫比亞
- 秘魯
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 埃及
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Alexion Pharmaceuticals, Inc.
Amgen Inc
AstraZeneca PLC
Baxter International
Bayer AG
Biogen
Bristol-Myers Squibb
Eli Lilly and Company
F. Hoffmann La Roche Ltd
GSK plc
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Pharmacyclics LLC
Sanofi SA
Seagen Inc.
Takeda Pharmaceutical Company Ltd.
Vertex Pharmaceutical Inc.

簡介目錄

Product Code: 3873

Global Rare Disease Treatment Market will reach a 9% CAGR from 2024 to 2032, attributed to advancements in medical research coupled with robust biopharmaceutical investments. Breakthroughs in gene therapies, precision medicine, and targeted treatments are reshaping therapeutic approaches. Moreover, increased funding and collaboration within the biopharmaceutical sector are accelerating the development of innovative therapies for rare diseases. These efforts enhance treatment options and address unmet medical needs, fostering a dynamic market environment focused on improving outcomes and quality of life for patients with rare diseases globally.

For instance, in April 2024, LifeArc initiated £40 million in research centers aimed at discovering novel tests, treatments, and cures for individuals affected by rare diseases. By fostering innovation in tests, treatments, and potential cures, LifeArc's initiative has the potential to accelerate breakthroughs, enhance patient outcomes, and expand the market's capacity for effective rare disease therapies on a global scale.

The rare disease treatment industry is classified based on drug type, therapeutic area, patient, route of administration, and region.

The injectable segment will see a notable surge between 2024 and 2032, owing to its efficacy and rapid onset of action. Many rare diseases require precise, targeted delivery of medication, which injectables provide. This method also ensures higher bioavailability compared to oral drugs. The rise in biologics and monoclonal antibodies, commonly administered via injection, further boosts this segment. Additionally, advancements in injection technologies and the growing prevalence of chronic rare diseases contribute to the injectable segment's market dominance.

The blood-related disorder segment will amass remarkable gains through 2032, propelled by the high prevalence of rare hematological conditions like hemophilia, thalassemia, and sickle cell anemia. These disorders often require specialized, long-term treatment and management, driving demand for innovative therapies. Advances in gene therapy, targeted treatments, and increasing research funding contribute to this segment's growth. Additionally, heightened awareness and improved diagnostic capabilities ensure that blood-related disorders remain a significant focus in the rare disease treatment market.

Asia Pacific will secure a substantial market presence from 2024 to 2032, driven by rising healthcare spending, expanding patient populations, and improving healthcare infrastructure. Countries like China, Japan, and India are investing heavily in rare disease research and treatment facilities. Additionally, increasing awareness among healthcare professionals and patients about rare diseases is boosting market growth in the region. Asia Pacific's pivotal contribution to advancements in medical research and innovation will further solidify its role as a key contributor to the rare disease treatment industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in the prevalence of rare diseases
  - 3.2.1.2 Favorable government policies
  - 3.2.1.3 Growing number of new drug launches
  - 3.2.1.4 Increasing R&D activities for novel therapeutics drugs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness regarding rare disease treatment
  - 3.2.2.2 High cost of the drugs and therapy
3.3 Growth potential analysis
3.4 Clinical trial scenario for rare disease treatment
3.5 Pipeline analysis
3.6 Future market trends
3.7 Technology landscape
3.8 Epidemiology scenario
3.9 Current therapies
3.10 Reimbursement scenario
3.11 Regulatory landscape
3.12 Porter's analysis
3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Biologics
5.3 Non-biologics

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cancer
6.3 Blood-related disorders
6.4 Central nervous system
6.5 Respiratory disorders
6.6 Musculoskeletal disorders
6.7 Cardiovascular disorders
6.8 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Patient, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Adult
7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Switzerland
- 9.3.8 Sweden
- 9.3.9 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Thailand
- 9.4.8 Vietnam
- 9.4.9 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Chile
- 9.5.5 Colombia
- 9.5.6 Peru
- 9.5.7 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Israel
- 9.6.5 Egypt
- 9.6.6 Rest of Middle East and Africa